MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14712598.2024.2428299

Медицинская библиотека · Expert opinion on biological therapy · 2024

Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies.

Lemke Lena, Blauvelt Andrew, Brückmann Ines, Cohen Hillel P, Fan Jamie, Guerrieri Davide, Horvat Matej, Poetzl Johann, Torella Claudia, Wang Qingfeng, von Richter Oliver

Сравнительное исследованиеСтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

To support an interchangeability designation for Sandoz adalimumab biosimilar (GP2017), antidrug antibody (ADA) signal-to-noise (S/N) ratios were assessed in the GP2017 ADACCESS trial to directly assess potential changes in immunogenicity.

RESEARCH DESIGN AND

METHODS

ADACCESS was a 51-week trial in patients with moderate-to-severe plaque psoriasis that included patients treated continuously with reference adalimumab (cH), and patients who experienced four switches between reference adalimumab and GP2017 (H2H). ADAs were measured every 6 weeks during the switching phase using an electrochemiluminescence assay. A non-parametric analysis was performed to estimate the 90% confidence interval (CI) of the median of difference in ADA S/N ratios between the cH and H2H treatment groups at week 41. If the 90% CI was within the margin of -0.16 to 0.16 (representing assay noise), this was considered a non-clinically meaningful difference in immunogenicity.

RESULTS

The 90% CIs of the median of difference in ADA S/N ratios between the two treatment groups were within the defined margin of -0.16 to 0.16 at week 41, and at all other time points. Efficacy and safety data were also similar between the treatment groups.

CONCLUSION

Analysis of ADA S/N ratios showed no increase in immunogenicity following up to four switches between reference adalimumab and GP2017.

TRIAL REGISTRATION: NCT02016105.

Для цитирования: Lemke Lena, Blauvelt Andrew, Brückmann Ines, Cohen Hillel P, Fan Jamie, Guerrieri Davide, Horvat Matej, Poetzl Johann, Torella Claudia, Wang Qingfeng, von Richter Oliver. Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies.. Expert opinion on biological therapy. 2024. DOI: 10.1080/14712598.2024.2428299.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.